Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding?

Area of Science:

• Gastroenterology
• Cardiology
• Clinical Practice

Background:

• Acute peptic ulcer bleeding in patients on low-dose aspirin for cardiovascular prevention poses a clinical challenge.
• Aspirin discontinuation increases cardiovascular event risk, yet optimal management for bleeding ulcers is unclear.
• Current practice often involves prolonged aspirin interruption, lacking strong evidence.

Purpose of the Study:

• To evaluate the outcomes of continuing versus stopping aspirin in patients with acute peptic ulcer bleeding.
• To propose an evidence-based management strategy for this patient population.
• To address the dilemma between cardiovascular protection and ulcer rebleeding risk.

Main Methods:

• Review of current clinical practice and limited available data.
• Analysis of outcomes in patients continuing aspirin post-endoscopic therapy and high-dose intravenous pantoprazole (PPI).
• Comparison of rebleeding rates and mortality between aspirin continuation and discontinuation groups.

Main Results:

• Continuing aspirin after successful endoscopic therapy and high-dose PPIs showed a small increase in rebleeding risk.
• Patients continuing aspirin had lower overall and cardiovascular 30-day mortality rates compared to those who stopped.
• Early reintroduction of aspirin within 5 days is suggested for secondary prevention patients.

Conclusions:

• Early endoscopic therapy followed by high-dose intravenous PPI and early aspirin reintroduction (within 5 days) is proposed for most patients.
• For primary prevention patients, aspirin cessation, re-evaluation, and delayed reintroduction post-discharge may be reasonable.
• Maintaining dual antiplatelet therapy is crucial in high-risk scenarios like recent coronary stent placement, favoring early endoscopy and PPIs.